The Lenovo IdeaPad Pro 5i is powered by Intel's top Arrow Lake-H processor, the Core Ultra 9 285H, features a gorgeous ...

In this video, I will go over Novo Nordisk's (NVO-1.22%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

The IdeaPad ... Perhaps Lenovo wanted to give the small fingerprint scanner below the arrow keys a lot of breathing room. I'd much rather move the fingerprint reader to the power button where ...

As of Feb. 5, get the Lenovo IdeaPad Flex 5i Chromebook for just $399 at Lenovo, down from its usual price of $400. That's ...

The $750 IdeaPad 5x 2-in-1 from Lenovo is another great Snapdragon X laptop, this time powered by the entry-level X Plus ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

You’re not going to be wowed by the Lenovo IdeaPad Slim 3. But, if you’re looking for a laptop that’s “good enough,” a phrase ...

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co-develop oral treatments for the red blood cell disorder and other ...

Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.